Insulet Corporation $PODD Stock Sold by One Way Holdings LLC

One Way Holdings LLC lessened its position in Insulet Corporation (NASDAQ:PODD) by 91.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,784 shares of the medical instruments supplier’s stock after selling 48,334 shares during the period. One Way Holdings LLC’s holdings in Insulet were worth $624,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Insulet during the third quarter valued at approximately $2,758,000. ProShare Advisors LLC lifted its position in Insulet by 6.0% in the 3rd quarter. ProShare Advisors LLC now owns 20,802 shares of the medical instruments supplier’s stock valued at $2,714,000 after acquiring an additional 1,185 shares in the last quarter. Vise Technologies Inc. lifted its position in Insulet by 52.9% in the 3rd quarter. Vise Technologies Inc. now owns 5,503 shares of the medical instruments supplier’s stock valued at $718,000 after acquiring an additional 1,903 shares in the last quarter. International Assets Investment Management LLC lifted its position in Insulet by 61,543.8% in the 3rd quarter. International Assets Investment Management LLC now owns 45,000 shares of the medical instruments supplier’s stock valued at $5,871,000 after acquiring an additional 44,927 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Insulet by 144.7% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,356 shares of the medical instruments supplier’s stock valued at $3,308,000 after acquiring an additional 14,996 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Wells Fargo & Company downgraded Insulet from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $255.00 to $144.00 in a research note on Wednesday, August 5th. UBS Group decreased their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Citigroup upped their price target on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Sanford C. Bernstein dropped their price objective on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Stifel Nicolaus dropped their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $186.68.

Insulet Stock Up 2.6%

Shares of Insulet stock opened at $153.61 on Tuesday. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average is $141.02 and its 200 day moving average is $179.25. The company has a market cap of $10.65 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.